effects of duloxetine and venlafaxine on the taxol-induced neuropathy

Phase 2

• Conditions: neuropathy.; Other disorders of peripheral nervous system

• Registration Number: IRCT20220115053723N1
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 February 2023

Recruitment & Eligibility

• Status: Complete
• Sex: Female
• Target Recruitment: 80

Inclusion Criteria

patients with breast cancer who treated with taxol (paclitaxel) for chemotherapy with peripheral neuropathic and neuropathic pain with confirmation of physical examination
pain score 3 or more according to MacGill questionnaire
No metastasis
life expectancy more than 3 months
Hospital anxiety and depression scale score less than 20 according to HADS questionnaire
Neuropathic score more than 3 in DN4 questionnaire.

Exclusion Criteria

metastatic breast cancer
pregnancy and breast feeding
HADS score more than 20
using antidepressant and anti epileptic drugs and opioids
paralytic neuropathic syndromes

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Pain score 3 or more according to MacGill questionnaire. Timepoint: At the beginning of the study and 10 weeks after starting the drug. Method of measurement: MacGill questionnaire.;Hospital anxiety and depression scale score less than 20 according to HADS questionnaire. Timepoint: At the beginning of the study and 10 weeks after starting the drug. Method of measurement: HADS questionnaire.;Neuropathic score more than 3 in DN4 questionnaire. Timepoint: At the beginning of the study and 10 weeks after starting the drug. Method of measurement: DN4 questionnaire.